AI assistant
Laurus Labs Limited — Call Transcript 2023
Apr 21, 2023
62639_rns_2023-04-21_89b772f4-a5ba-47b8-bb28-ff93a5561357.pdf
Call Transcript
Open in viewerOpens in your device viewer
LAURUS LABS LIMITED
==> picture [114 x 37] intentionally omitted <==
LAURUS LABS LTD. Q4 & FULL YEAR FY23 RESULTS CONFERENCE CALL ON THURSDAY, 27TH APRIL 2023 AT 5:00 PM IST
Laurus Labs Ltd. (Laurus), a leading research and development driven pharmaceutical company in India, will organize a conference call for Investors and Analysts, on Thursday, 27th April 2023 at 5:00 PM IST
The conference call will be initiated with a brief management discussion on the Q4 & Full year FY23 results, followed by an interactive Question & Answer session. The call will be hosted by Antique Stock Broking.
Details of the conference call are as follows:
For Diamond pass please Copy this URL in your browser:
https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=4223928&linkSecurityString=1595809f68
| Timing | 5:00pm IST on April 27, 2023 |
|---|---|
| Conference dial-in | |
| PrimaryNumber | +91 22 6280 1342 |
| SecondaryNumber | +91 22 7115 8243_Available all over India_ |
| Singapore | 800101 2045 |
| HongKong | 800964 448 |
| Japan | 00531161110 |
| USA | 1 866 746 2133 |
| UK | 0 808 101 1573 |
VENKATESW Digitally signed by VENKATESWAR REDDY AR REDDY GOGIREDDY Date: 2023.04.21 GOGIREDDY 09:52:09 +05'30'
APRIL 21, 2023
PAGE 2
==> picture [113 x 36] intentionally omitted <==
About Laurus Labs Ltd.
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company with an aim to improve the quality of life for millions around the world. We have a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. We also offer integrated CMO and Contract Development and Manufacturing Organization (CDMO) services to Global Innovators from drug development to commercial manufacturing both in Drug substance (DS) and in Drug product (DP).
We are passionate about continuous technological advances for Smart and Green chemistry skills to driven efficiencies and sustainable manufacturing backed by proven regulatory track record and quality foundation. Laurus employs 5700+ people, including around 800+ scientists at more than 8 facilities approved by major regulatory agencies USFDA, WHO-Geneva, Japan-PDMA, UKMHRA, EMA, TGA etc. During FY2022 Laurus generated over ₹ 4,900 crore in annual revenue and is listed on the BSE (Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. Laurus' proactive stance to conduct business with utmost Transparency, Integrity and Respect for environment & communities have earned it a place in Governance benchmark, consistently Certified Great Place to Work and Rated “BBB” by leading MSCI ESG Ratings.
For more information visit www.lauruslabs.com
Corporate Identification No: L24239AP2005PLC047518
For further information, please contact
Vivek Kumar Laurus Labs Limited Tel: +91 40 6659 4366 Email: [email protected]
VENKATES Digitally signed by VENKATESWAR WAR REDDY REDDY GOGIREDDY Date: 2023.04.21 GOGIREDDY 09:52:34 +05'30'
APRIL 21, 2023